DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the LYKA LABS LTD. (LYKALABS) share price today?

LYKA LABS LTD. (LYKALABS) is trading at ₹70.13 on the NSE, up 1.11% on the day. Source: DocStoX.

What is the market capitalisation of LYKA LABS LTD.?

LYKA LABS LTD. has a market capitalisation of approximately ₹248 crore.

LYKA LABS LTD.

LYKALABS·NSE·Healthcare

₹70.13▲ +0.77 (+1.11%)

Healthcare · Pharmaceuticals

A steady, established business

Day₹68.75

₹70.85

52W₹44

₹12134%

Open

₹70.20

High

₹70.85

Low

₹68.75

Prev Close

₹69.36

Volume

12.9K

VWAP

₹69.41

Snapshot

Key fundamentals

Market Cap

₹248 Cr

P/E Ratio

N/A

P/B Ratio

2.79

EPS

₹-2.81

Book Value

₹25.90

ROE

-10.20%Weak

ROCE

-6.00%Weak

Dividend Yield

0.00%

Debt / Equity

0.53Moderate

Face Value

₹10.00

52W High

₹121.44

52W Low

₹44.10

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatHigh uncertainty

Fair value estimate

₹19

▼ 72.9%downside

Trading at ₹70 — 73% above our estimate

BearFair valueBull

₹16₹19₹22

/100

Business quality — Watch the fundamentals

Growth 45Profitability 0Efficiency 0Valuation 74

Plain English

Our view

A steady, established business
Promoters hold a controlling stake
Weak returns on equity (-10%)

Strengths

Promoters hold a controlling stake

Risks

Weak returns on equity (-10%)
Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

—

ROE

-10.2%Weak

Above 15% is considered healthy for Indian equities

ROCE

-6.0%Weak

Above 18% means capital is working hard

Debt/Eq

0.53Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹248 Cr

P/B

2.79

EPS

₹-2.81

Div Yield

—

What changed

Recent changes

Foreign investors+0.1% stake last quarter

What matters

News impact

Overview

Valuation

N/A

No P/E

Growth

Steady

+11% rev CAGR

Profitability

Loss-making

-10.2% ROE

Financial health

Comfortable

D/E 0.53

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹8.92L Cr

Trades40

VWAP₹69.41

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+11.2%

+8.3%

10Y

-0.1%

Profit

—

10Y

—

EPS

—

10Y

—

Profile

Pros

Company's working capital requirements have reduced from 32.4 days to 22.8 days

Watch-outs

Cons

Stock is trading at 2.74 times its book value
Company has low interest coverage ratio.
The company has delivered a poor sales growth of 8.29% over past five years.
Company has a low return on equity of -2.04% over last 3 years.
Company might be capitalizing the interest cost

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors bought 0.12 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

58%

Promoter

Promoters

58.2%0.00

Public

40.9%-0.10

FII / FPI

0.3%+0.12

DII

0.7%0.00

Total shareholders

26,727-428 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter58.16%

FII0.29%

DII0.66%

Public40.89%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1976, Lyka Labs Ltd is in the development, manufacture and marketing of quality finished dosages[1]

LYKA LABS LTD. valuation & research

Deep-dive tools with DocStoX's fair-value estimate, ratios and peers.

Fair Value Intrinsic Value DCF Valuation Financial Ratios Peers

LYKA LABS LTD. peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

SUN PHARMACEUTICAL IND L DIVI S LABORATORIES LTD TORRENT PHARMACEUTICALS L APOLLO HOSPITALS ENTER. L ZYDUS LIFESCIENCES LTD CIPLA LTD LUPIN LIMITED MAX HEALTHCARE INS LTD MANKIND PHARMA LIMITED DR. REDDY S LABORATORIES AUROBINDO PHARMA LTD LAURUS LABS LIMITED

Compare LYKA LABS LTD. with peers

LYKA LABS LTD. vs SUN PHARMACEUTICAL IND L LYKA LABS LTD. vs DIVI S LABORATORIES LTD LYKA LABS LTD. vs TORRENT PHARMACEUTICALS L LYKA LABS LTD. vs APOLLO HOSPITALS ENTER. L LYKA LABS LTD. vs ZYDUS LIFESCIENCES LTD LYKA LABS LTD. vs CIPLA LTD

LYKA LABS LTD.

Key fundamentals

Key statistics

Recent changes

News impact

Overview

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership breakdown

Ownership over time

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Frequently asked questions

LYKA LABS LTD. valuation & research

LYKA LABS LTD. peers in Healthcare

Compare LYKA LABS LTD. with peers

Key statistics

Recent changes

News impact

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Ownership breakdown

Ownership over time

Frequently asked questions